PhotoCure ASA (FRA:PHS) Growth Rank: 7 (As of Jul. 16, 2026) — 40% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PHS PhotoCure ASA FRA:PHS
70 GF Score
Price €5.08
GF Value €6.29
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is PhotoCure ASA Growth Rank?

PhotoCure ASA FRA:PHS -2.50% 70 Growth Rank is 7 as of Jul. 16, 2026, which is 40% above its 10-year median of 5.00. GuruFocus rates FRA:PHS with a GF Score™ of 70/100 and a GF Value™ of €6.29 (Modestly Undervalued). The stock has 1 warning sign investors should review.

PhotoCure ASA has the Growth Rank of 7.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

FRA:PHS vs ZTS, UTHR, VTRS: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PhotoCure ASA's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PhotoCure ASA Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PhotoCure ASA's Growth Rank distribution charts can be found below:

* The bar in red indicates where PhotoCure ASA's Growth Rank falls into.


FRA:PHS
70GF Score
PhotoCure ASA FRA:PHS
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 7 mean?
PhotoCure ASA (FRA:PHS) has a Growth Rank of 7 as of Jul. 16, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on PhotoCure ASA and its competitors. This is 40% above median its historical median of 5.00. Over the past decade, PhotoCure ASA's Growth Rank has ranged from 2.00 to 8.00.
Is PhotoCure ASA's Growth Rank too high?
PhotoCure ASA's current Growth Rank of 7 is 40% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 8.00. Overall, PhotoCure ASA has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhotoCure ASA's Growth Rank compare to ZTS and UTHR?
PhotoCure ASA's Growth Rank of 7 can be compared against companies in the Drug Manufacturers industry. Historically, PhotoCure ASA's own Growth Rank has ranged from 2.00 to 8.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on PhotoCure ASA and its competitors. PhotoCure ASA's current Growth Rank is 7, which is 40% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhotoCure ASA stock overvalued right now?
Based on GuruFocus' analysis, PhotoCure ASA (FRA:PHS) is currently considered Modestly Undervalued. The stock's GF Value™ is €6.29, compared to a current price of €5.08 — trading 19.2% below its estimated fair value. The current Growth Rank is 7, which is 40% above median its 10-year median of 5.00. PhotoCure ASA's overall GF Score™ is 70/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For PhotoCure ASA (FRA:PHS), the current Growth Rank is 7 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PhotoCure ASA (FRA:PHS) Overvalued in 2026?

Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued. The current stock price of €5.08 is trading 19.2% below its estimated GF Value™ of €6.29. GuruFocus considers PhotoCure ASA to be Modestly Undervalued.

Key valuation signals for FRA:PHS:

  • Growth Rank: 7 (40% above median its 10-year median of 5.00)
  • GF Value™: €6.29 vs. price of €5.08 (19.2% below fair value)
  • GF Score™: 70/100 with 1 warning sign

No single metric tells the full story. See the FRA:PHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PhotoCure ASA Business Description

Address Hoffsveien 4, Oslo, NOR, 0275
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
70GF Score

Get the complete analysis for FRA:PHS

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.08
Price
€6.29
GF Value